Earnings behind it, the rally continues
Bristol-Myers Squibb stock: +5.2% after earnings, technical structure shows no warnings
Earnings behind it, the rally continues
Our view last week
Bristol-Myers Squibb shares close the confirmation week higher, +2.2%, with price still glued to its recent highs: a level already tested multiple times, where a straight breakout stays risky. Earnings land this very week, on July 30, and raise the stakes on every move. Our weekly technical analysis reads a solid but not-yet-broken setup, with volume and money flow staying lukewarm.
This week's summary
Bristol-Myers Squibb stock climbs 5.2% during earnings week, and the weekly structure shows not a single warning across 11 components. Seven days ago the confirmation week closed up 2.2% near the highs; now the stock extends further, with buyers commanding 83.6% of volume. Our weekly technical analysis on this pharma stock reads a solid picture, with the buy signal confirmed in its second week.
IQS Phase
74
in tension
Signal Strength
47
medium · weak
Sizing
REDUCED
Ranking
#68 / 120
US stocks in progress
Trade P&L %
+7.52%
from signal to date, no stop loss
Rank position
ranks 68th among the 120 Longs already running for US stocks in our ranking, with a signal strength of 47 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly -0.01% · monthly +1.89%
BMY belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content